

chain nodes :

12 13 14 15 16 17 18 19

ring nodes :

1 2 3 4 5 6 7 8 9 10 11

chain bonds :

1-15 4-12 5-17 5-18 12-13 13-14 15-16 15-19

ring bonds :

1-2 1-7 2-3 2-8 3-4 3-11 4-5 5-6 6-7 8-9 9-10 10-11

exact/norm bonds :

1-2 1-7 1-15 3-4 4-5 5-6 6-7 13-14 15-16 15-19

exact bonds :

4-12 5-17 5-18 12-13

normalized bonds :

2-3 2-8 3-11 8-9 9-10 10-11

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom

10/554,150

=> d his

(FILE 'HOME' ENTERED AT 10:49:48 ON 03 APR 2006)

FILE 'REGISTRY' ENTERED AT 10:50:45 ON 03 APR 2006

L1 STRUCTURE UPLOADED

L2 18 S L1

L3 342 S L1 SSS FUL


FILE 'CAPLUS' ENTERED AT 10:51:27 ON 03 APR 2006

L4 2 S L3

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.


=> d ibib abs hitstr total

10/554,150


applicant

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:965226 CAPLUS
DOCUMENT NUMBER: 141:395433
TITLE: Preparation of 4,4-difluoro-1,2,3,4-tetrahydro-1(5H)-
benzazepine derivatives for treatment of night
pollakisuria and diabetes insipidus
INVENTOR(S): Koshio, Hiroyuki; Tsukamoto, Issei; Kakefuda, Akio;
Akamatsu, Seihiro; Saitoh, Chikashi
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096775	A1	20041111	WO 2004-JP5998	20040426
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2521492	AA	20041111	CA 2004-2521492	20040426
EP 1619185	A1	20060125	EP 2004-729502	20040426
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2005187449	A2	20050714	JP 2004-130664	20040427
PRIORITY APPLN. INFO.:			JP 2003-123032	A 20030428
			JP 2003-401126	A 20031201
			WO 2004-JP5998	W 20040426
OTHER SOURCE(S):		MARPAT 141:395433		
GI				



I



II

AB The title 4,4-difluoro-1,2,3,4-tetrahydro-1(5H)-benzazepine derivs. represented by the general formula I [wherein R1 = (un)substituted NH2, OH, or alkoxy; R2 = CF3 or halo; R3 = H or halo; X = CH=CH, CH=N, N=N, S, or N; Y = CH, N, or S; A = O, S, NH, or -N-alkylene-; B = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, or aryl] or pharmaceutically acceptable salts thereof are prepared as arginine vasopressin V2 receptor stimulator. For example, the compound II was prepared in a multi-step synthesis. I showed affinity towards human arginine vasopressin V2 receptor with Ki of 4.3-19 nM. I are useful for the treatment of night pollakisuria and/or diabetes insipidus (no data).

IT 790695-19-1P 790695-21-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of tetrahydrobenzazepine derivs. for treatment of night pollakisuria and diabetes insipidus)

RN 790695-19-1 CAPLUS

CN Acetamide, N-(2-amino-2-oxoethyl)-2-[1-[(2-chloro-6-propoxy-3-pyridinyl)carbonyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 790695-21-5 CAPLUS

CN Acetamide, 2-[1-[(2-chloro-6-propoxy-3-pyridinyl)carbonyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

10/554,150



REFERENCE COUNT:

30

THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:612094 CAPLUS
 DOCUMENT NUMBER: 129:245172
 TITLE: Preparation of 4,4-difluoro-2,3,4,5-tetrahydro-1H-1-benzazepine derivatives as oxytocin antagonists
 INVENTOR(S): Matsuhisa, Akira; Murakami, Takeshi; Sakuda, Shuichi; Kawano, Noriyuki; Shibasaki, Kumiko; Tanaka, Akihiro
 PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 66 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9839325	A1	19980911	WO 1998-JP916	19980305
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2281518	AA	19980911	CA 1998-2281518	19980305
AU 9861204	A1	19980922	AU 1998-61204	19980305
EP 987264	A1	20000322	EP 1998-905779	19980305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
US 6340678	B1	20020122	US 1999-380683	19990902
PRIORITY APPLN. INFO.:			JP 1997-52163	A 19970306
			WO 1998-JP916	W 19980305

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title 4,4-Difluoro-2,3,4,5-tetrahydro-1H-1-benzazepine derivs. represented by formula (I) or salts thereof (wherein A is 5-membered heteroaryl; B is optionally substituted aryl or 5- or 6-membered heteroaryl; D is carbonyl or lower alkylene; R1 is -NR3R4, -O-(lower alkyl) or OH; R2 is optionally halogenated lower alkyl, -O-(lower alkyl), -S-(lower alkyl) or -CO-(lower alkyl); R3 and R4 are each independently hydrogen, lower alkyl or the like; and n is 0, 1 or 2). The above compds. exhibit the oxytocin antagonism and are effective in inhibiting threatened premature birth or abortion, or precesarean birth and useful as remedies for dysmenorrhea and so on (no data). Thus, 1H-benzoazepin-5-ylideneacetic acid derivative (II; R = OH) was condensed with 2-(piperazin-1-yl)ethanol using DCC at room temperature for 18 h to give II (R

=

Q).

IT 213023-64-4

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of difluorotetrahydrobenzazepine derivs. as oxytocin antagonists)

RN 213023-64-4 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-

thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[1-(phenylmethyl)-4-piperidinyl]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 213020-98-5P 213020-99-6P 213021-00-2P

213021-01-3P 213021-02-4P 213021-03-5P


RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
USES (Uses)

(preparation of difluorotetrahydrobenzazepine derivs. as oxytocin antagonists)

RN 213020-98-5 CAPLUS

CN Acetic acid, [4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-, methyl ester, (2Z)- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 213020-99-6 CAPLUS

CN Acetic acid, [4,4-difluoro-1,2,3,4-tetrahydro-1-[[1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbonyl]-5H-1-benzazepin-5-ylidene]-, methyl ester, (2Z)- (9CI) (CA INDEX NAME)

10/554,150


Double bond geometry as shown.



RN 213021-00-2 CAPLUS

CN Acetic acid, [4,4-difluoro-1,2,3,4-tetrahydro-1-[(5-methyl-1-phenyl-1H-pyrazol-4-yl)carbonyl]-5H-1-benzazepin-5-ylidene]-, methyl ester, (2Z)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213021-01-3 CAPLUS

CN Acetic acid, [4,4-difluoro-1,2,3,4-tetrahydro-1-[[1-phenyl-5-(trifluoromethyl)-1H-imidazol-4-yl]carbonyl]-5H-1-benzazepin-5-ylidene]-, methyl ester, (2Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT	213021-04-6P	213021-05-7P	213021-06-8P
	213021-07-9P	213021-09-1P	213021-10-4P
	213021-11-5P	213021-12-6P	213021-15-9P
	213021-16-0P	213021-17-1P	213021-18-2P
	213021-20-6P	213021-21-7P	213021-22-8P
	213021-23-9P	213021-24-0P	213021-25-1P
	213021-26-2P	213021-27-3P	213021-28-4P
	213021-29-5P	213021-31-9P	213021-32-0P
	213021-33-1P	213021-34-2P	213021-35-3P
	213021-36-4P	213021-37-5P	213021-38-6P
	213021-39-7P	213021-40-0P	213021-41-1P
	213021-43-3P	213021-44-4P	213021-45-5P
	213021-46-6P	213021-47-7P	213021-48-8P
	213021-49-9P	213021-50-2P	213021-51-3P
	213021-52-4P	213021-53-5P	213021-54-6P
	213021-55-7P	213021-56-8P	213021-58-0P
	213021-59-1P	213021-60-4P	213021-63-7P
	213021-66-0P	213021-67-1P	213021-68-2P
	213021-69-3P	213021-70-6P	213021-71-7P
	213021-72-8P	213021-73-9P	213021-74-0P
	213021-75-1P	213021-76-2P	213021-77-3P
	213021-78-4P	213021-79-5P	213021-80-8P
	213021-81-9P	213021-82-0P	213021-84-2P
	213021-85-3P	213021-86-4P	213021-87-5P
	213021-88-6P	213021-89-7P	213021-90-0P
	213021-91-1P	213021-92-2P	213021-93-3P
	213021-94-4P	213021-95-5P	213021-96-6P
	213021-97-7P	213021-98-8P	213021-99-9P
	213022-00-5P	213022-02-7P	213022-03-8P
	213022-04-9P	213022-05-0P	213022-06-1P
	213022-07-2P	213022-08-3P	213022-09-4P
	213022-10-7P	213022-11-8P	213022-12-9P
	213022-13-0P	213022-15-2P	213022-16-3P
	213022-17-4P	213022-18-5P	213022-19-6P
	213022-20-9P	213022-21-0P	213022-22-1P
	213022-23-2P	213022-24-3P	213022-25-4P
	213022-27-6P	213022-28-7P	213022-29-8P
	213022-30-1P	213022-31-2P	213022-32-3P
	213022-33-4P	213022-34-5P	213022-35-6P
	213022-36-7P	213022-37-8P	213022-38-9P
	213022-39-0P	213022-40-3P	213022-41-4P
	213022-42-5P	213022-43-6P	213022-44-7P
	213022-45-8P	213022-46-9P	213022-47-0P

213022-48-1P 213022-49-2P 213022-50-5P
 213022-51-6P 213022-52-7P 213022-53-8P
 213022-54-9P 213022-55-0P 213022-56-1P
 213022-57-2P 213022-58-3P 213022-59-4P
 213022-60-7P 213022-61-8P 213022-62-9P
 213022-63-0P 213022-64-1P 213022-65-2P
 213022-66-3P 213022-67-4P 213022-68-5P
 213022-69-6P 213022-70-9P 213022-71-0P
 213022-73-2P 213022-74-3P 213022-75-4P
 213022-77-6P 213022-79-8P 213022-81-2P
 213022-82-3P 213022-84-5P 213022-85-6P
 213022-86-7P 213022-87-8P 213022-89-0P
 213022-91-4P 213022-93-6P 213022-94-7P
 213022-95-8P 213022-96-9P 213022-97-0P
 213022-99-2P 213023-00-8P 213023-01-9P
 213023-02-0P 213023-03-1P 213023-04-2P
 213023-05-3P 213023-06-4P 213023-07-5P
 213023-08-6P 213023-14-4P 213023-15-5P
 213023-16-6P 213023-17-7P 213023-18-8P
 213023-19-9P 213023-20-2P 213023-21-3P
 213023-22-4P 213023-23-5P 213023-24-6P
 213023-25-7P 213023-26-8P 213023-27-9P
 213023-28-0P 213023-29-1P 213023-30-4P
 213023-31-5P 213023-32-6P 213023-33-7P
 213023-34-8P 213023-35-9P 213023-36-0P
 213023-37-1P 213023-38-2P 213023-39-3P
 213023-40-6P 213023-41-7P 213023-42-8P
 213023-43-9P 213023-44-0P 213023-45-1P
 213023-46-2P 213023-47-3P 213023-48-4P
 213023-49-5P 213023-50-8P 213023-51-9P
 213023-52-0P 213023-53-1P 213023-55-3P
 213023-56-4P 213023-57-5P 213023-58-6P
 213023-59-7P 213026-24-5P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of difluorotetrahydrobenzazepine derivs. as oxytocin antagonists)

RN 213021-04-6 CAPLUS

CN Acetic acid, [4,4-difluoro-1,2,3,4-tetrahydro-1-[(5-methyl-1-phenyl-1H-pyrazol-4-yl)carbonyl]-5H-1-benzazepin-5-ylidene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




10/554,150

RN 213021-05-7 CAPLUS

CN Acetic acid, [4,4-difluoro-1,2,3,4-tetrahydro-1-[[1-phenyl-5-(trifluoromethyl)-1H-imidazol-4-yl]carbonyl]-5H-1-benzazepin-5-ylidene]-, (2Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213021-06-8 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-[4-(2-hydroxyethyl)-1-piperazinyl]-2-oxoethylidene]-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213021-07-9 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-oxo-2-(4-oxo-1-piperidinyl)ethylidene]-, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



RN 213021-09-1 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-(4-hydroxy-1-piperidiny)-2-oxoethylidene]-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, (5Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213021-10-4 CAPLUS

CN 4-Piperidinecarboxamide, 1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-, (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



RN 213021-11-5 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-(4-methyl-1-piperazinyl)-2-oxoethylidene]-, dihydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




●2 HCl

RN 213021-12-6 CAPLUS

CN 1H-1-Benzazepine, 5-[2-(4-ethyl-1-piperazinyl)-2-oxoethylidene]-4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, dihydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



RN 213021-15-9 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-[4-(1-methylethyl)-1-piperazinyl]-2-oxoethylidene]-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, dihydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213021-16-0 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-[4-(2-hydroxyethyl)-1-piperazinyl]-2-oxoethylidene]-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, dihydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

10/554,150




RN 213021-17-1 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-[4-(2-methoxyethyl)-1-piperazinyl]-2-oxoethylidene]-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, dihydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 2-A


RN 213021-18-2 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-5-[2-(hexahydro-4-methyl-1H-1,4-diazepin-1-

10/554,150

yl)-2-oxoethylidene]-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213021-20-6 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-[4-(3-hydroxypropyl)-1-piperazinyl]-2-oxoethylidene]-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, dihydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 2-A


●2 HCl

RN 213021-21-7 CAPLUS

CN 1-Piperazineacetamide, 4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

●2 HCl

RN 213021-22-8 CAPLUS

CN 4-Piperidineacetamide, 1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-, (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213021-23-9 CAPLUS

CN 1-Piperazinepropanamide, 4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




●2 HCl

RN 213021-24-0 CAPLUS

CN 1-Piperazinepropanoic acid, 4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213021-25-1 CAPLUS

CN 1-Piperazinepropanoic acid, 4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]- β -oxo-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



RN 213021-26-2 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(dimethylamino)ethyl]-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213021-27-3 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-(2-hydroxyethyl)-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



RN 213021-28-4 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-(4-hydroxybutyl)-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213021-29-5 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N,N-bis(2-hydroxyethyl)-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



RN 213021-31-9 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[1-(phenylmethyl)-4-piperidinyll]-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213021-32-0 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(1-pyrrolidinyll)ethyl]-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213021-33-1 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(1-piperidinyl)ethyl]-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213021-34-2 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(tetrahydro-2H-pyran-4-yl)ethyl]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



RN 213021-35-3 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213021-36-4 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-oxo-2-(1-piperidiny)ethylidene]-, (5Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



RN 213021-37-5 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-(4-morpholinyl)-2-oxoethylidene]-, (5Z)-(9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 213021-38-6 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-oxo-2-(4-thiomorpholinyl)ethylidene]-, (5Z)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.

10/554,150



RN 213021-39-7 CAPLUS
CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-(4-methoxy-1-piperidinyl)-2-oxoethylidene]-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, (5Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213021-40-0 CAPLUS
CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-[2-(hydroxymethyl)-1-piperidinyl]-2-oxoethylidene]-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



RN 213021-41-1 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-[3-(hydroxymethyl)-1-piperidinyl]-2-oxoethylidene]-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213021-43-3 CAPLUS

CN 1H-1-Benzazepine, 5-[2-[4-[(acetyloxy)methyl]-1-piperidinyl]-2-oxoethylidene]-4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



RN 213021-44-4 CAPLUS

CN 1H-1-Benzazepine, 5-[2-[4-[2-(acetyloxy)ethyl]-1-piperidinyl]-2-oxoethylidene]-4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, (5Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213021-45-5 CAPLUS

CN Carbamic acid, [1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213021-46-6 CAPLUS

CN Acetamide, N-[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidiny]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213021-47-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213021-48-8 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-[4-(4-morpholinyl)-1-piperidinyl]-2-oxoethylidene]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213021-49-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)

10/554,150


Double bond geometry as shown.



RN 213021-50-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213021-51-3 CAPLUS

CN Carbamic acid, [2-[4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-1-piperazinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/554,150


Double bond geometry as shown.



RN 213021-52-4 CAPLUS

CN 1H-1-Benzazepine, 5-[2-[4-(cyanomethyl)-1-piperazinyl]-2-oxoethylidene]-4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, dihydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213021-53-5 CAPLUS

CN 1-Piperazineacetic acid, 4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



RN 213021-54-6 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-oxo-2-(4-phenyl-1-piperazinyl)ethylidene]-, monohydrochloride, (5Z)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213021-55-7 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-[4-(2-methylphenyl)-1-piperazinyl]-2-oxoethylidene]-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, monohydrochloride, (5Z)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213021-56-8 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethylidene]-, monohydrochloride, (5Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213021-58-0 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-oxo-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethylidene]-, monohydrochloride, (5Z)-(9CI) (CA INDEX NAME)

10/554,150


Double bond geometry as shown.



RN 213021-59-1 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-2-pyridinyl-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213021-60-4 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-3-pyridinyl-, (2Z)- (9CI)

10/554,150

(CA INDEX NAME)


Double bond geometry as shown.



RN 213021-63-7 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-(phenylmethyl)-, (2Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213021-66-0 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-(2-pyridinylmethyl)-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

10/554,150




● HCl

RN 213021-67-1 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-(3-pyridinylmethyl)-, monohydrochloride, (2Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213021-68-2 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-(4-pyridinylmethyl)-, monohydrochloride, (2Z)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213021-69-3 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[[1-(triphenylmethyl)-1H-imidazol-4-yl]methyl]-, (2Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213021-70-6 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(1H-imidazol-4-yl)ethyl]-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213021-71-7 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-oxo-2-(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethylidene]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.




● HCl

RN 213021-72-8 CAPLUS

CN 1H-1-Benzazepine, 5-[2-(7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-oxoethylidene]-4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

10/554,150

Double bond geometry as shown.




● HCl

RN 213021-73-9 CAPLUS

CN 5H-Pyrido[3,2-b]azepine, 5-[[[(5Z)-4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-6,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 213021-74-0 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]-2-oxoethylidene]-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, dihydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 213021-75-1 CAPLUS
 CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-[4-[2-(4-morpholinyl)ethyl]-1-piperazinyl]-2-oxoethylidene]-, trihydrochloride, (5Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




● 3 HCl

RN 213021-76-2 CAPLUS

CN 1H-1-Benzazepine, 5-[2-[4-[2-(dimethylamino)ethyl]-1-piperazinyl]-2-oxoethylidene]-4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, dihydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

●2 HCl

RN 213021-77-3 CAPLUS
 CN 1H-1-Benzazepine, 5-[2-[4-(dimethylamino)-1-piperidinyl]-2-oxoethylidene]-4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, dihydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




●2 HCl

RN 213021-78-4 CAPLUS

10/554,150

CN 4-Piperidinecarboxamide, 1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-N-methoxy-N-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213021-79-5 CAPLUS

CN Acetic acid, [1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyldene]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213021-80-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)

10/554,150

ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213021-81-9 CAPLUS

CN 1-Piperazinepropanoic acid, 4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213021-82-0 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-oxo-2-(3-oxo-1-piperazinyl)ethylidene]-, (5Z)- (9CI) (CA INDEX NAME)

10/554,150


Double bond geometry as shown.



RN 213021-84-2 CAPLUS

CN 1-Piperazineacetamide, 4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213021-85-3 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[4-(2-hydroxyethyl)-1-piperazinyl]-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213021-86-4 CAPLUS

CN Glycine, N-[[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidiny]carbonyl]-N-ethyl-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213021-87-5 CAPLUS

CN β-Alanine, N-[[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidiny]carbonyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213021-88-6 CAPLUS

CN Glycine, N-[[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213021-89-7 CAPLUS

CN 4-Piperidinepropanoic acid, 1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213021-90-0 CAPLUS

CN Glycine, N-[[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidiny]carbonyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213021-91-1 CAPLUS

CN 4-Piperidinepropanoic acid, 1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-β-oxo-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213021-92-2 CAPLUS

CN Propanoic acid, 3-[[[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213021-93-3 CAPLUS

CN Acetic acid, [[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213021-94-4 CAPLUS

CN Acetic acid, [[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyloxy]-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213021-95-5 CAPLUS

CN 2-Propenoic acid, 3-[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyloxy]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213021-96-6 CAPLUS

CN 1-Piperazineacetic acid, 4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-α,α-dimethyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213021-97-7 CAPLUS

CN 1H-1-Benzazepine, 5-[2-(4-cyclopropyl-1-piperazinyl)-2-oxoethylidene]-4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

10/554,150


Double bond geometry as shown.



RN 213021-98-8 CAPLUS

CN 1-Piperazineacetic acid, 4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-α-methyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213021-99-9 CAPLUS

CN 1-Piperazinepropanoic acid, 4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

10/554,150

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

●2 HCl

RN 213022-00-5 CAPLUS

CN Butanoic acid, 4-[[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyl]amino]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-02-7 CAPLUS

CN Propanoic acid, 3-[[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidiny]methylamino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-03-8 CAPLUS

CN β -Alanine, N-[[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidiny]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-04-9 CAPLUS

Acetamide, 2-[[1-[(5Z)-4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyl]methylamino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-05-0 CAPLUS

CN 4-Piperidinepropanamide, 1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-N-[2-(dimethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213022-06-1 CAPLUS

CN β -Alanine, N-[3-[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyl]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213022-07-2 CAPLUS

CN 1-Piperazinebutanamide, 4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 2-A


● HCl

10/554,150

RN 213022-08-3 CAPLUS

CN 1-Piperazineacetamide, 4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-09-4 CAPLUS

CN β -Alanine, N-[[4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-1-piperazinyl]acetyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



PAGE 1-A


PAGE 2-A

● HCl

RN 213022-10-7 CAPLUS
 CN 1H-1-Benzazepine, 5-[2-[4-[[[(dimethylamino)acetyl]oxy]imino]-1-piperidinyl]-2-oxoethylidene]-4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

● HCl

RN 213022-11-8 CAPLUS
 CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-(4-methyl-1-piperazinyl)-2-oxoethylidene]-1-[[1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbonyl]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213022-12-9 CAPLUS

CN 4-Piperidineacetic acid, 1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[[1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-13-0 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-[4-(2-hydroxyethyl)-1-piperazinyl]-2-oxoethylidene]-1-[[1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbonyl]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213022-15-2 CAPLUS

CN 1-Piperazineacetamide, 4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[[1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213022-16-3 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-[4-(3-hydroxypropyl)-1-piperazinyl]-2-oxoethylidene]-1-[[1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbonyl]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



RN 213022-17-4 CAPLUS

CN 1-Piperazinepropanamide, 4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[[1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213022-18-5 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(5-methyl-1-phenyl-1H-pyrazol-4-yl)carbonyl]-5-[2-(4-methyl-1-piperazinyl)-2-oxoethylidene]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

10/554,150




● HCl

RN 213022-19-6 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-oxo-2-(4-oxo-1-piperidinylethylidene)-1-[[1-phenyl-5-(trifluoromethyl)-1H-imidazol-4-yl]carbonyl]-, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213022-20-9 CAPLUS

CN 1H-1-Benzazepine, 5-[2-[4-[(acetyloxy)methyl]-1-piperidinyl]-2-oxoethylidene]-4,4-difluoro-2,3,4,5-tetrahydro-1-[[1-phenyl-5-(trifluoromethyl)-1H-imidazol-4-yl]carbonyl]-, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



RN 213022-21-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[[1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-22-1 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-[4-(hydroxymethyl)-1-piperidinyl]-2-oxoethylidene]-1-[[1-phenyl-5-(trifluoromethyl)-1H-imidazol-4-yl]carbonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-23-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-24-3 CAPLUS

CN 1-Piperazineacetic acid, 4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-25-4 CAPLUS

CN 1-Piperazinepropanoic acid, 4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-27-6 CAPLUS


CN 4-Piperidinepropanoic acid, 1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213022-28-7 CAPLUS
 CN Acetic acid, [[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyl]oxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 213022-29-8 CAPLUS
 CN 2-Propenoic acid, 3-[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-30-1 CAPLUS

CN Acetic acid, [[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyldene]amino]oxy]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-31-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-32-3 CAPLUS

CN 1-Piperazineacetic acid, 4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-α-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-33-4 CAPLUS

CN 1-Piperazineacetic acid, 4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-34-5 CAPLUS

CN 1-Piperazinepropanoic acid, 4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-
β-oxo- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213022-35-6 CAPLUS

CN 1-Piperazinebutanoic acid, 4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



RN 213022-36-7 CAPLUS

CN β -Alanine, N-[[4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-1-piperazinyl]acetyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-37-8 CAPLUS

CN Glycine, N-[[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-38-9 CAPLUS

CN Glycine, N-[[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyloxy]carbonyl]-N-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-39-0 CAPLUS

CN Propanoic acid, 3-[[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyloxy]amino]-3-oxo- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-40-3 CAPLUS

CN Acetic acid, [[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidiny]methoxy]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-41-4 CAPLUS

CN Butanoic acid, 4-[[[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidiny]amino]-4-oxo- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-42-5 CAPLUS

CN Propanoic acid, 3-[[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidiny]methylamino]-3-oxo- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213022-43-6 CAPLUS

CN β-Alanine, N-[[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



RN 213022-44-7 CAPLUS

CN Glycine, N-[[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidiny]carbonyl]-N-ethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213022-45-8 CAPLUS

CN β -Alanine, N-[[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidiny]carbonyl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



RN 213022-46-9 CAPLUS

CN Glycine, N-[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyldene]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213022-47-0 CAPLUS

CN 4-Piperidinepropanoic acid, 1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-β-hydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



RN 213022-48-1 CAPLUS

CN β -Alanine, N-[3-[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213022-49-2 CAPLUS

CN 1H-1-Benzazepine, 1-[(5-ethyl-1-phenyl-1H-pyrazol-4-yl)carbonyl]-4,4-difluoro-2,3,4,5-tetrahydro-5-[2-(4-methyl-1-piperazinyl)-2-oxoethylidene]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

10/554,150




● HCl

RN 213022-50-5 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-(4-methyl-1-piperazinyl)-2-oxoethylidene]-1-[(1-phenyl-5-propyl-1H-pyrazol-4-yl)carbonyl]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213022-51-6 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-(4-methyl-1-piperazinyl)-2-oxoethylidene]-1-[(1-phenyl-5-(trifluoromethyl)-1H-imidazol-4-yl)carbonyl]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

10/554,150


Double bond geometry as shown.



RN 213022-52-7 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-(4-methyl-1-piperazinyl)-2-oxoethylidene]-1-[(1-phenyl-1H-pyrazol-4-yl)carbonyl]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213022-53-8 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-(4-methyl-1-piperazinyl)-2-oxoethylidene]-1-[(1-phenyl-1H-pyrazol-3-yl)carbonyl]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

10/554,150

Double bond geometry as shown.




● HCl

RN 213022-54-9 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(5-methyl-1-phenyl-1H-pyrazol-3-yl)carbonyl]-5-[2-(4-methyl-1-piperazinyl)-2-oxoethylidene]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213022-55-0 CAPLUS

CN 1H-1-Benzazepine, 1-[(4,5-dimethyl-1-phenyl-1H-pyrazol-3-yl)carbonyl]-4,4-difluoro-2,3,4,5-tetrahydro-5-[2-(4-methyl-1-piperazinyl)-2-oxoethylidene]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

10/554,150


Double bond geometry as shown.



RN 213022-56-1 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-(4-methyl-1-piperazinyl)-2-oxoethylidene]-1-[[4-phenyl-5-(trifluoromethyl)-2-thienyl]carbonyl]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213022-57-2 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(5-methyl-4-phenyl-2-oxazolyl)carbonyl]-5-[2-(4-methyl-1-piperazinyl)-2-oxoethylidene]-, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



RN 213022-58-3 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(5-methyl-4-phenyl-2-thiazolyl)carbonyl]-5-[2-(4-methyl-1-piperazinyl)-2-oxoethylidene]-, (5Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213022-59-4 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-(4-methyl-1-piperazinyl)-2-oxoethylidene]-1-[(1-phenyl-1H-pyrazol-5-yl)carbonyl]-, monohydrochloride, (5Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

10/554,150




● HCl

RN 213022-60-7 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(3-methyl-1-phenyl-1H-pyrazol-5-yl)carbonyl]-5-[2-(4-methyl-1-piperazinyl)-2-oxoethylidene]-, monohydrochloride, (5Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213022-61-8 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(5-methyl-3-phenyl-4-isoxazolyl)carbonyl]-5-[2-(4-methyl-1-piperazinyl)-2-oxoethylidene]-, monohydrochloride, (5Z)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.

10/554,150



RN 213022-62-9 CAPLUS
CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl

RN 213022-63-0 CAPLUS
CN Acetamide, 2-[1-[(4-ethyl-2-phenyl-5-thiazolyl)carbonyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl

RN 213022-64-1 CAPLUS
 CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methoxy-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl

RN 213022-65-2 CAPLUS
 CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[[2-phenyl-4-(trifluoromethyl)-5-thiazolyl]carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213022-66-3 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[[4-methyl-2-(2-methylphenyl)-5-thiazolyl]carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213022-67-4 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[[4-methyl-2-(3-methylphenyl)-5-thiazolyl]carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213022-68-5 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[[4-methyl-2-(4-methylphenyl)-5-thiazolyl]carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213022-69-6 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[[4-methyl-2-[2-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)

10/554,150


Double bond geometry as shown.



● HCl

RN 213022-70-9 CAPLUS
CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213022-71-0 CAPLUS
CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[[2-(2-methoxyphenyl)-4-methyl-5-thiazolyl]carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)

10/554,150

Double bond geometry as shown.




● HCl

RN 213022-73-2 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[[2-(3-methoxyphenyl)-4-methyl-5-thiazolyl]carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213022-74-3 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[[2-(4-methoxyphenyl)-4-methyl-5-thiazolyl]carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)-(9CI) (CA INDEX NAME)

10/554,150

Double bond geometry as shown.




● HCl

RN 213022-75-4 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1-[[2-(2-fluorophenyl)-4-methyl-5-thiazolyl]carbonyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213022-77-6 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1-[[2-(3-fluorophenyl)-4-methyl-5-thiazolyl]carbonyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)

10/554,150

Double bond geometry as shown.




● HCl

RN 213022-79-8 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1-[[2-(4-fluorophenyl)-4-methyl-5-thiazolyl]carbonyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213022-81-2 CAPLUS

CN Acetamide, 2-[1-[[2-(3-chlorophenyl)-4-methyl-5-thiazolyl]carbonyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)-(9CI) (CA INDEX NAME)

10/554,150

Double bond geometry as shown.




● HCl

RN 213022-82-3 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(2-phenyl-4-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, (2Z)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-84-5 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(5-phenyl-2-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, (2Z)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-85-6 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(5-phenyl-3-isoxazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213022-86-7 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(2-methyl-5-phenyl-3-furanyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

10/554,150




● HCl

RN 213022-87-8 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(2-methyl-5-phenyl-3-thienyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213022-89-0 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(5-methyl-2-phenyl-4-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

10/554,150




● HCl

RN 213022-91-4 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(3-methyl-5-phenyl-2-thienyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213022-93-6 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-oxazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

10/554,150




● HCl

RN 213022-94-7 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(5-methyl-2-phenyl-1H-imidazol-4-yl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, dihydrochloride, (2Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




●2 HCl

RN 213022-95-8 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(3-methyl-1-phenyl-1H-pyrazol-4-yl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl

RN 213022-96-9 CAPLUS
 CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl

RN 213022-97-0 CAPLUS
 CN Acetamide, 2-[1-[(5-acetyl-2-phenyl-4-thiazolyl)carbonyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, (2Z)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213022-99-2 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[[3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, (2Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213023-00-8 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(5-methyl-1-phenyl-1H-pyrazol-4-yl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl

RN 213023-01-9 CAPLUS
 CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[[1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213023-02-0 CAPLUS
 CN Acetamide, 2-[1-[(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)carbonyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



RN 213023-03-1 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(1-phenyl-1H-imidazol-4-yl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213023-04-2 CAPLUS

CN Acetamide, 2-[1-[[5-(4-chlorophenyl)-2-formyl-3-furanyl]carbonyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl

RN 213023-05-3 CAPLUS
 CN Acetamide, 2-[1-[[5-(4-chlorophenyl)-2-(trifluoromethyl)-3-furanyl]carbonyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213023-06-4 CAPLUS
 CN Acetamide, 2-[1-[[5-(4-chlorophenyl)-2-methyl-3-furanyl]carbonyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)

10/554,150

Double bond geometry as shown.




● HCl

RN 213023-07-5 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[[4-methyl-2-(3-pyridinyl)-5-thiazolyl]carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, dihydrochloride, (2Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




●2 HCl

RN 213023-08-6 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[[4-methyl-2-(4-pyridinyl)-5-thiazolyl]carbonyl]-5H-1-benzazepin-5-ylidene]-N-[2-(4-morpholinyl)ethyl]-, dihydrochloride, (2Z)-(9CI) (CA INDEX NAME)

10/554,150

Double bond geometry as shown.




● 2 HCl

RN 213023-14-4 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-[4-[(4-morpholinyl)methyl]-1-piperidinyl]-2-oxoethylidene]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213023-15-5 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-[4-(2-hydroxyethyl)-1-piperidinyl]-2-oxoethylidene]-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



RN 213023-16-6 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-[4-(hydroxymethyl)-1-piperidinyl]-2-oxoethylidene]-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, (5Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213023-17-7 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-4-piperidinyl-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213023-18-8 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-(1-methyl-4-piperidiny)-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213023-19-9 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-(4-piperidinylmethyl)-, dihydrochloride, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



● 2 HCl

RN 213023-20-2 CAPLUS
CN 1H-1-Benzazepine, 5-[2-(4-amino-1-piperidiny)-2-oxoethylidene]-4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, monohydrochloride, (5Z)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl

RN 213023-21-3 CAPLUS
CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-oxo-2-(1-piperazinyl)ethylidene]-, (5Z)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213023-22-4 CAPLUS
 CN 1H-1-Benzazepine, 5-[2-[4-(2-aminoethyl)-1-piperidinyl]-2-oxoethylidene]-4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, dihydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 2-A


● 2 HCl

RN 213023-23-5 CAPLUS
 CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-[4-(methylamino)-1-

10/554,150

piperidinyll]-2-oxoethylidene]-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-
, (5Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213023-24-6 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-[(4-(hydroxyimino)-1-piperidinyll]-2-oxoethylidene]-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-
, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213023-25-7 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-[(4-(methoxyimino)-1-piperidinyll]-2-oxoethylidene]-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-
, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



RN 213023-26-8 CAPLUS

CN 1H-1-Benzazepine, 5-[2-[4-(ethoxyimino)-1-piperidinyl]-2-oxoethylidene]-4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, (5Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213023-27-9 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-[4-[[2-(4-morpholinyl)ethoxy]imino]-1-piperidinyl]-2-oxoethylidene]-, dihydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● 2 HCl

RN 213023-28-0 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-oxo-2-[4-[(4-pyridinylmethoxy)imino]-1-piperidinyl]ethylidene]-, dihydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 2-A


● 2 HCl

RN 213023-29-1 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-oxo-2-[4-[(3-pyridinylmethoxy)imino]-1-piperidinyl]ethylidene]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

● HCl

RN 213023-30-4 CAPLUS
 CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-oxo-2-[4-[(2-pyridinylmethoxy)imino]-1-piperidinyl]ethylidene]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

● HCl

RN 213023-31-5 CAPLUS
 CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-[4-[1-(hydroxyimino)ethyl]-1-piperidinyl]-2-oxoethylidene]-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.


10/554,150



RN 213023-32-6 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-oxo-2-[4-[[[1-(triphenylmethyl)-1H-imidazol-4-yl]methoxy]imino]-1-piperidinyl]ethylidene]-, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213023-33-7 CAPLUS

CN Acetic acid, [1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinylidene]hydrazide (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



RN 213023-34-8 CAPLUS

CN 1H-1-Benzazepine, 5-[2-[4-[(acetyloxy)imino]-1-piperidinyl]-2-oxoethylidene]-4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, (5Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213023-35-9 CAPLUS

CN Acetamide, N-[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213023-36-0 CAPLUS

CN 1-Piperazinebutanoic acid, 4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]- γ -oxo- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213023-37-1 CAPLUS

CN Glycine, N-acetyl-N-[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



RN 213023-38-2 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-(1H-imidazol-4-ylmethyl)-, (2Z)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213023-39-3 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-5-[2-[4-[(1H-imidazol-4-ylmethoxy)imino]-1-piperidinyl]-2-oxoethylidene]-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, monohydrochloride, (5Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213023-40-6 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-oxo-2-[4-[2-(1H-tetrazol-5-yl)ethyl]-1-piperazinyl]ethylidene]-, (5Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213023-41-7 CAPLUS

CN 1H-1-Benzazepine, 5-[2-(4-acetyl-1-piperidinyl)-2-oxoethylidene]-4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, (5Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213023-42-8 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-oxo-2-[4-[2-[(phenylmethyl)amino]ethyl]-1-piperidinyl]ethylidene]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 213023-43-9 CAPLUS
 CN Glycine, N-[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyl]-N-(trifluoroacetyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/554,150



RN 213023-44-0 CAPLUS

CN Glycine, N-[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213023-45-1 CAPLUS

CN Glycine, N-[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyl]-, (9CI) (CA INDEX NAME)

10/554,150


Double bond geometry as shown.



RN 213023-46-2 CAPLUS

CN Acetamide, 2-[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyldene]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213023-47-3 CAPLUS

CN Acetamide, 2-[1-[[[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyldene]amino]oxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213023-48-4 CAPLUS

CN Acetamide, 2-[[[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinylidene]amino]oxy]-N-[2-(dimethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 2-A


● HCl

10/554,150

RN 213023-49-5 CAPLUS

CN Acetic acid, [[[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinylidene]amino]oxy]-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213023-50-8 CAPLUS

CN Glycine, N-[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyl]-N-methyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 213023-51-9 CAPLUS

10/554,150

CN Carbamic acid, [1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213023-52-0 CAPLUS

CN Glycine, N-[1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-4-piperidinyl]-N-(trifluoroacetyl)-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




10/554,150

RN 213023-53-1 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-oxo-2-[4-[2-[2-(triphenylmethyl)-2H-tetrazol-5-yl]ethyl]-1-piperazinyl]ethylidene]-, (5Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213023-55-3 CAPLUS

CN 1-Piperazineacetic acid, 4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-2-oxo- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




10/554,150

RN 213023-56-4 CAPLUS

CN 1-Piperazineacetic acid, 4-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213023-57-5 CAPLUS

CN 1H-1-Benzazepine, 5-[2-(4-acetyl-1-piperazinyl)-2-oxoethylidene]-4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




10/554,150

RN 213023-58-6 CAPLUS

CN 1H-1-Benzazepine, 5-[2-[4-(1,3-dihydroxypropyl)-1-piperidinyl]-2-oxoethylidene]-4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-, (5Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 213023-59-7 CAPLUS

CN 4-Piperidinepropanoic acid, 1-[(2Z)-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]acetyl]-β-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




10/554,150

RN 213026-24-5 CAPLUS

CN Acetamide, 2-[4,4-difluoro-1,2,3,4-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5H-1-benzazepin-5-ylidene]-N-[3-(4-morpholinyl)propyl]-, monohydrochloride, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT:

23

THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT